Current applications and future perspectives of sirolimus in the treatment of kaposiform hemangioendothelioma

References:

[1] Wassef M,Blei F,Adams D,et al.Vascular anomalies classification:recommendations from the International Society for the Study of Vascular Anomalies[J].Pediatrics,2015,136(1):e203-e214.DOI:10.1542/peds.2014-3673.
[2] Schmid I,Klenk AK,Sparber-Sauer M,et al.Kaposiform hemangioendothelioma in children:a benign vascular tumor with multiple treatment options[J].World J Pediatr,2018,14(4):322-329.DOI:10.1007/s12519-018-0171-5.
[3] Ji Y,Chen S,Yang K,et al.Kaposiform hemangioendothelioma:current knowledge and future perspectives[J].Orphanet J Rare Dis,2020,15(1):39.DOI:10.1186/s13023-020-1320-1.
[4] O’Rafferty C,O’Regan GM,Irvine AD,et al.Recent advances in the pathobiology and management of Kasabach-Merritt phenomenon[J].Br J Haematol,2015,171(1):38-51.DOI:10.1111/bjh.13557.
[5] 姚祥,王珊.儿童脉管性疾病的诊治进展[J].现代医药卫生,2016,32(18):2824-2827.DOI:10.3969/j.issn.1009-5519.2016.18.014.Yao X,Wang S.Recent advances in the diagnosis and treatment of pediatric vascular diseases[J].J Mod Med Health,2016,32(18):2824-2827.DOI:10.3969/j.issn.1009-5519.2016.18.014.
[6] Rodriguez V,Lee A,Witman PM,et al.Kasabach-merritt phenomenon:case series and retrospective review of the mayo clinic experience[J].J Pediatr Hematol Oncol,2009,31(7):522-526.DOI:10.1097/MPH.0b013e3181a71830.
[7] Bennett ML,Fleischer AB Jr,Chamlin SL,et al.Oral corticosteroid use is effective for cutaneous hemangiomas:an evidence-based evaluation[J].Arch Dermatol,2001,137(9):1208-1213.DOI:10.1001/archderm.137.9.1208.
[8] Wang Z,Li K,Yao W,et al.Steroid-resistant kaposiform hemangioendothelioma:A retrospective study of 37 patients treated with vincristine and long-term follow-up[J].Pediatr Blood Cancer,2015,62(4):577-580.DOI:10.1002/pbc.25296.
[9] Liu XH,Li JY,Qu XH,et al.Treatment of kaposiform hemangioendothelioma and tufted angioma[J].Int J Cancer,2016,139(7):1658-1666.DOI:10.1002/ijc.30216.
[10] Yao W,Li K,Wang Z,et al.Comparison of corticosteroid and vincristine in treating kaposiform hemangioendothelioma and tufted angioma:a systematic review and meta-analysis[J].Eur J Pediatr Surg,2019,29(5):401-407.DOI:10.1055/s-0038-1673708.
[11] Wang H,Duan Y,Gao Y,et al.Sirolimus for vincristine-resistant Kasabach-Merritt phenomenon:report of eight patients[J].Pediatr Dermatol,2017,34(3):261-265.DOI:10.1111/pde.13077.
[12] Blatt J,Stavas J,Moats-Staats B,et al.Treatment of childhood kaposiform hemangioendothelioma with sirolimus[J].Pediatric Blood&Cancer,2010,55(7):1396-1398.DOI:10.1002/pbc.22766.
[13] Wang H,Guo X,Duan Y,et al.Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma[J].Pediatric Dermatology,2018,35(5):635-638.DOI:10.1111/pde.13600.
[14] Sandbank S,Molho-Pessach V,Farkas A,et al.Oral and topical sirolimus for vascular anomalies:a multicentre study and review[J].Acta dermato-venereologica,2019,99(11):990-996.DOI:10.2340/00015555-3262.
[15] Freixo C,Ferreira V,Martins J,et al.Efficacy and safety of sirolimus in the treatment of vascular anomalies:A systematic review[J].J Vasc Surg,2020,71(1):318-327.DOI:10.1016/j.jvs.2019.06.217.
[16] Mahajan P,Margolin J,Iacobas I.Kasabach-Merritt Phenomenon:classic presentation and management options[J].Clin Med Insights Blood Disord,2017,10:1179545X-17699849.DOI:10.1177/1179545X17699849.
[17] Wang D,Chen X,Li Z.Population pharmacokinetics of sirolimus in pediatric patients with kaposiform hemangioendothelioma:A retrospective study[J].Oncol Lett,2019,18(3):2412-2419.DOI:10.3892/ol.2019.10562.
[18] Macdonald A,Scarola J,Burke JT,et al.Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus[J].Clin Ther,2000,22:B101-B121.DOI:10.1016/S0149-2918(00)89027-X.
[19] Czechowicz JA,Long-Boyle JR,Rosbe KW,et al.Sirolimus for management of complex vascular anomalies-A proposed dosing regimen for very young infants[J].Int J Pediatr Otorhinolaryngol,2018,105:48-51.DOI:10.1016/j.ijporl.2017.11.034.
[20] Adams DM,Trenor RCC,Hammill AM,et al.Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J].Pediatrics,2016,137(2):e20153257.DOI:10.1542/peds.2015-3257.
[21] Ji Y,Chen S,Xiang B,et al.Sirolimus for the treatment of progressive kaposiform hemangioendothelioma:A multicenter retrospective study[J].Int J Cancer,2017,141(4):848-855.DOI:10.1002/ijc.30775.
[22] Wang Z,Yao W,Sun H,et al.Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up[J].J Dermatol,2019,46(11):956-961.DOI:10.1111/1346-8138.15076.
[23] Russell TB,Rinker EK,Dillingham CS,et al.Pneumocystis jirovecii pneumonia during sirolimus therapy for kaposiform hemangioendothelioma[J].Pediatrics,2018,141(Suppl 5):S421-S424.DOI:10.1542/peds.2017-1044.
[24] Tan X,Zhang J,Zhou S,et al.Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus[J].J Dermatol,2018,45(5):580-583.DOI:10.1111/1346-8138.14231.
[25] Sethia R,Cerne JW,Jatana KR,et al.Pediatric facial kaposiform hemangioendothelioma:a case report and review of the literature[J].J Surg Case Rep,2019,2019(4):rjz113.DOI:10.1093/jscr/rjz113.
[26] Sakata N,Suenobu SI,Okano M,et al.Impact of sirolimus treatment for refractory kaposiform hemangioendothelioma with exacerbation of the disease 10 years after initial diagnosis[J].Rare Tumors,2018,10:1152527630.DOI:10.1177/2036361318776185.
[27] Chinello M,Di Carlo D,Olivieri F,et al.Successful management of kaposiform hemangioendothelioma with long-term sirolimus treatment:a case report and review of the literature[J].Mediterr J Hematol Infect Dis,2018,10(1):e2018043.DOI:10.4084/MJHID.2018.043.
[28] Drolet BA,Trenor CC 3rd,Brand?o LR,et al.Consensus-derived practice standards plan for complicated kaposiform hemangioendothelioma[J].J Pediatr,2013,163(1):285-291.DOI:10.1016/j.jpeds.2013.03.080.
[29] Shetty AK,Winter MA.Immunization of children receiving immunosuppressive therapy for cancer or hematopoietic stem cell transplantation[J].Ochsner J,2012,12(3):228-243.
[30] Esposito S,Cecinati V,Brescia L,et al.Vaccinations in children with cancer[J].Vaccine,2010,28(19):3278-3284.DOI:10.1016/j.vaccine.2010.02.096.
[31] Papp KA,Haraoui B,Kumar D,et al.Vaccination Guidelines for Patients With Immune-Mediated Disorders on Immunosuppressive Therapies[J].J Cutan Med Surg,2019,23(1):50-74.DOI:10.1177/1203475418811335.
[32] Han JH,Harmoney KM,Dokmeci E,et al.Dynamic re-immunization of off-treatment childhood cancer survivors:An implementation feasibility study[J].PLoS One,2018,13(2):e191804.DOI:10.1371/journal.pone.0191804.
[33] Mustafa MM,Bunchanan GR,Winick NJ,et al.Immune recovery in children with malignancy after cessation of chemotherapy[J].J Pediatr Hematol Oncol,1998,20(5):451-457.DOI:10.1097/00043426-199809000-00008.
[34] Ruggiero A,Battista A,Coccia P,et al.How to manage vaccinations in children with cancer[J].Pediatric Blood Cancer,2011,57(7):1104-1108.DOI:10.1002/pbc.23333.
[35] Abzug MJ.Vaccination in the immunocompromised child:a probe of immune reconstitution[J].Pediatr Infect Dis J,2009,28(3):233-236.DOI:10.1097/INF.0b013e31819d31bc.